RxDoctor Payments Data

Alexander Sosenko, MD

Pulmonary Disease · Joliet, ILNPI 1851383780

Payments from drug & device makers

$356in general payments, 2019–2025

Across 21 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$139
  • AstraZeneca$50
  • Sanofi$43
  • Boehringer Ingelheim$33
  • Ambu Inc.$27
  • Mallinckrodt Hospital Products Inc.$25
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$34196%
  • Education$154%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$356 in reported general payments places this provider in the 30th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$129,590
Medicare patients
359
Services billed
1,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter156$154,973
Breo ElliptaFluticasone/Vilanterol148$70,655
Spiriva RespimatTiotropium Bromide61$38,130
Fluticasone-SalmeterolFluticasone Propion/Salmeterol135$25,907
Incruse ElliptaUmeclidinium Bromide57$24,222
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$22,542
Wixela InhubFluticasone Propion/Salmeterol83$12,760
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$11,517
SymbicortBudesonide/Formoterol Fumarate24$11,303
Albuterol Sulfate HfaAlbuterol Sulfate274$9,090
Spiriva HandihalerTiotropium Bromide13$6,754
DuleraMometasone/Formoterol18$6,048
BreynaBudesonide/Formoterol Fumarate11$5,784
Arnuity ElliptaFluticasone Furoate12$5,703
Montelukast Sodium220$2,548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$139$278,096416 claims
Boehringer IngelheimSpiriva Respimat$33$38,13061 claims
AstraZenecaBreztri Aerosphere, Symbicort$50$22,82137 claims
MerckDulera$24$6,04818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Joliet

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →